KAPA's Equity Line Can Swamp Its Entire Float Five Times Over

A 1-for-7 reverse split shrank Kairos Pharma's free-trading supply to roughly 2.46 million shares, but a Cayman-domiciled equity line retains $26.8 million of undrawn capacity — enough, at today's levels, to theoretically issue more than 17 million new shares into a 3.39-million-share company.